Modality
Peptide
MOA
HPK1i
Target
WRN
Pathway
RNA Splicing
NSCLCNB
Development Pipeline
Preclinical
~Dec 2023
→ ~Mar 2025
Phase 1
Jun 2025
→ Dec 2025
Phase 1Current
NCT08706988
2,082 pts·NSCLC
2025-06→2025-12·Not yet recruiting
2,082 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-124mo agoInterim· NSCLC
Trial Timeline
Q3Q4
P1
Not yet…
Catalysts
Interim
2025-12-12 · 4mo ago
NSCLC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08706988 | Phase 1 | NSCLC | Not yet recr... | 2082 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |